Ładuje się......
Performance of (89)Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
PURPOSE: Treatment of patients with diffuse large B cell lymphoma (DLBCL) includes rituximab, an anti-CD20 monoclonal antibody (mAb). Insufficient tumor targeting might cause therapy failure. Tumor uptake of (89)Zirconium ((89)Zr)-mAb is a potential imaging biomarker for tumor targeting, since it de...
Zapisane w:
| Wydane w: | PLoS One |
|---|---|
| Główni autorzy: | , , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Public Library of Science
2017
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5218417/ https://ncbi.nlm.nih.gov/pubmed/28060891 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0169828 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|